Delivery Order SPE2DR25D3009-SPE2DR26FWHE7
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $11,535.36 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units). This is a firm fixed-price, non-set-aside contract with an ultimate completion date of December 16, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical federal vendor specializing in medical procurement for military and veteran healthcare systems. The delivery...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $4,595.10 on December 16, 2025, for the supply of Ondansetron ODT 8 mg tablets in quantities of 30. The contract represents a firm fixed-price delivery order with an ultimate completion date of December 17, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. This award was competitively awarded without set-aside provisions, consistent with...
- The Defense Logistics Agency awarded a delivery order valued at $1,284.44 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count packages). The award, issued on January 6, 2026, with an ultimate completion date of January 7, 2026, represents a firm fixed-price delivery order with no set-aside designation. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters. This delivery order...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $3,371.93 delivery order for Ondansetron ODT 4 mg tablets (30-count) on November 28, 2025, with an ultimate completion date of December 1, 2025. This is a firm fixed-price, non-set-aside contract executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 through December 2026. The product will be performed at AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $1,888.29 for Ondansetron ODT 8 mg tablets (30-count packages) on January 5, 2026, with completion scheduled for January 6, 2026. This contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract under...
- The Defense Logistics Agency awarded a delivery order valued at $2,644.86 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 8 mg tablets in quantities of 30, with an ultimate completion date of December 8, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $1,151.89 to AmerisourceBergen Drug Corp for Ondansetron ODT 8 mg tablets (30-count packages), with an ultimate completion date of December 23, 2025. This competitively awarded, firm fixed-price delivery order was issued with no set-aside designation. The pharmaceutical product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a major pharmaceutical distributor and critical vendor...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Ondansetron ODT 8 mg tablets (30-count) valued at $2,744.16, with an ultimate completion date of July 22, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement. The place of performance is the...
- The Defense Logistics Agency awarded a delivery order valued at $32,253.76 to AmerisourceBergen Drug Corp on January 7, 2026, for the supply of Ondansetron ODT 8mg tablets in a 30-count package. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of February 4, 2026. The place of performance is located in Conshohocken, Pennsylvania, which serves as the company's corporate headquarters. AmerisourceBergen Drug Corp, a major...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,498.54 to AmerisourceBergen Drug Corp on December 3, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 units. This is a firm fixed price, non-set-aside contract with a completion date of December 4, 2025. The award was issued to AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, the company's headquarters and place of performance. This delivery order operates under...
- SPE2DR25D3009Indefinite Delivery Contract
- SPE2DR25D3009-SPE2DR26FWHE7Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $8,035.99 to AmerisourceBergen Drug Corp for Ondansetron ODT 4 mg tablets (30 count) on January 8, 2026, with a completion date of January 9, 2026. This is a firm fixed-price, non-set-aside contract with performance taking place at AmerisourceBergen's Conshohocken, Pennsylvania location. The award represents a task order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, a $999,999,999 vehicle running through December 2026 that enables the company to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc. (formerly doing business as AmerisourceBergen), is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement. The company's substantial IDC with DLA demonstrates its capability to efficiently fulfill government contracts for essential pharmaceutical and medical commodities required by military treatment facilities and veterans' healthcare programs. Ondansetron, an anti-nausea medication commonly used in medical settings, represents one of many pharmaceutical products the company supplies through its federal contracting relationships. This award was competitively awarded with no set-aside designation.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.0k | 1/7/26 |